title: [Alendronate treatment of osteoporosis secondary to Duchenne muscular dystrophy].
abstract: BACKGROUND
  Reduced mobility and glucocorticoids as adjunctive therapy causes osteoporosis in Duchenne muscular dystrophy. Alendronate has been used in childhood osteoporosis of other aetiologies with good results and no adverse effects.
  
  
  METHODS
  Three patients with Duchenne dystrophy, symptoms of bone involvement (prior history of generalized bone pain and fractures) and bone mineral density (BMD) by dual-energy X-ray absorptiometry with Z-score ≤-2 SD. Treatment with oral alendronate was initiated (10mg/day).
  
  
  RESULTS
  There was an increase in lumbar (L2-L4) BMD in all cases, with improvement of bone pain. No fractures and adverse effects were observed during follow up.
  
  
  CONCLUSIONS
  Oral alendronate produces an increase in BMD in these patients, with good tolerance and no need for hospitalization, and so improves quality of life and reduces health care costs.
authors.affiliation: Unidad de Endocrinología Pediátrica, Hospital General de Ciudad Real, Ciudad Real, Spain. palomo.enrique@gmail.com
authors.forename: E
authors.initials: E
authors.lastname: Palomo Atance
authors.forename: M J
authors.initials: MJ
authors.lastname: Ballester Herrera
authors.forename: M A
authors.initials: MA
authors.lastname: Márquez de La Plata
authors.forename: E
authors.initials: E
authors.lastname: Medina Cano
authors.forename: R M
authors.initials: RM
authors.lastname: Carmona Vilchez
mesh_terms: D019386:Alendronate / Q000627:therapeutic use*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D002648:Child; D006801:Humans; D020388:Muscular Dystrophy, Duchenne / Q000150:complications*; D010024:Osteoporosis / Q000188:drug therapy* / Q000209:etiology*
chemical_list: D050071:Bone Density Conservation Agents; D019386:Alendronate